Get the full Fathom Therapeutics company profile
Access contacts, investors, buying signals & more
Fathom Therapeutics has raised $47.0M in Series A funding. The company pairs quantum chemistry with AI to design novel drug molecules, predicting how they'll behave inside living cells.
That's the pitch behind its Microcosmos drug discovery engine, which Fathom says it's built to model molecular behavior in the cellular environment where drugs actually have to work. The company did not disclose its investors.
The AIxBio Series A rounds of 2026 (so far)* 🧬 1/ Warp Sciences 🇺🇸 · $215M · AI + robotic chemistry labs 2/ Collate 🇺🇸 · $95M · AI for drug development paperwork 3/ Infinimmune 🇺🇸 · $75M · human antibodies + antibody language models 4/ Biorce 🇪🇸 · $52.
5M · AI for clinical trial design 5/ Xellar Biosystems 🇺🇸 · $50M (A + A+) · organ-on-chip + AI virtual cell 6/ Fathom Therapeutics 🇺🇸 · $47M · physics + AI small-molecule design 7/ Adaptyv 🇨🇭 · $40M · automated wet lab for AI protein design 8/ Biolevate 🇫🇷 · €30M · AI agents for regulated pharma workflows 9/ Beyang Therapeutics 🇨🇳 · $30M · AI-driven small-molecule design 10/ Converge Bio
Recursive
Recursive self-improving superintelligence to automate knowledge discovery.
$650.0M Series a
today
Private Fleet Net Zero
Private Fleet Net Zero is the first to match backhaul capacity from high-quality Private Fleet trucks, which are 45% of the trucks on the road and are empty ~80% on their backhaul trips, to available loads from 3PLs.
$2.0M Seed
today
Circularity Fuels
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 |  NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Recursive United States | Series a | $650.0M | today |
| 2 |  Claimlane Denmark | Series a | $6.3M | today |
Circularity Fuels is on a mission to decarbonize hard-to-abate sectors by turning waste streams into valuable products, starting with converting agricultural biogas into sustainable aviation fuel. Founded by former U.S. Air Force Petroleum Office Deployed Lab Chief Dr. Stephen Beaton, the company emerged from DCVC’s entrepreneur-in-residence program. Its proprietary Ouro Reactor, based on modified automotive catalytic converter technology, achieves methane reforming at a fraction of the cost and scale of traditional industrial equipment. The company has secured $8 million in seed funding and grants from VC firms, the National Science Foundation, California Energy Commission, and others. To learn more, visit www.circularityfuels.com.
$7.0M Seed
today
| $7.2B |
| 2y ago |
| 3 |  GRAIL United States | Unknown | $7.1B | 2y ago |
| 4 |  Illumina United States | Unknown | $7.1B | 2y ago |
| 5 |  RemeGen Biosciences United States | Grant | $5.6B | 9mo ago |
| 3 |
 Uncover Brazil |
| Series a |
| $16.0M |
| today |
| 4 |  LARQ United States | Series a | $10.0M | today |
| 5 |  URobotics Corp. | Series a | $29.8M | today |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
See who invested in Fathom Therapeutics and reach their contacts directly.
Start free trial
Nyquis
Recently received
Proofbacked
Recently received
Yurideks
Recently received
